partnering | pharmaphorum

Friday 30 October 2026

partnering

News

US Treasury proposes curbs on Chinese biotech deals

US Treasury proposes curbs on Chinese biotech deals

China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.

News

Roche offers $15bn for strategic-level deal with Hansoh

Roche offers $15bn for strategic-level deal with Hansoh

A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.

News

Zealand Pharma and Generate Biomedicines logos on light blue background

Zealand forges obesity alliance with AI specialist Generate

Zealand has added another strand to its programme of weight-loss drug development, linking with AI player Generate on multispecific protein therapies.

News

Alentis Therapeutics symbol

CSL joins forces with Alentis on claudin candidate

CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.

News

Novartis taps China's Abogen for autoimmunity TCE

Novartis taps China's Abogen for autoimmunity TCE

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

Sanofi and Regeneron logos on grey background

Sanofi forges new $8bn pact with Regeneron

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.